• Concerns grow about CDC’s tracking, securing dangerous pathogens under its supervision

    Last week, Centers for Disease Control and Prevention(CDC) officials reported that the same federal scientist who found vials of smallpox in a Food and Drug Administration(FDA) cold storage room at the National Institutes of Healthfacility in Bethesda, Maryland, also found a collection of 327 vials which could contain pathogens like dengue, influenza, and rickettsia. The new revelation adds to growing concerns about the government’s ability to track and secure dangerous pathogens under its supervision.”It is ironic that the institution that sets U.S. standards for safety and security of work with human pathogens fails to meet its own standards,” says a security expert. “It is clear that the CDC cannot be relied upon to police its own select-agent labs.”

  • Head of biosecurity advisory panel: Board is stalling as a result of slow fed policy work

    The head of a federal biosecurity advisory committee says delays in the development of a national policy on institutional oversight of risky life-sciences research are the main reason the committee has been inactive for close to two years. The dormancy of the National Science Advisory Board for Biosecurity (NSABB) was pushed into the spotlight this week with the revelation that the eleven remaining original members of the 23-member board are being replaced. The board was set up in 2005 to advise the government on biosecurity and dual-use research, meaning research that can be exploited for harm as well as good.

  • Investigation finds serious violations of safety rules in CDC’s handling of deadly germs

    An investigation by the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service(APHIS) conducted a review, from 23 June to 3 July, of the Centers for Disease Control and Prevention(CDC), and cited the agency for failing to follow proper procedures before and after the anthrax scare which led to the potential exposure of more than eighty lab workers to live anthrax viruses in June.APHIS found multiple violations of federal rules for handling dangerous microbes.

  • Following accidents, CDC shuts down anthrax, flu labs

    Federal officials announced on Friday that they had temporarily closed the flu and anthrax laboratories at the Centers for Disease Control and Prevention (CDC) in Atlanta and halted shipments of all infectious agents from the agency’s highest-security labs. The announcement followed revelations about two recent accidents involving deadly agents at the CDC campus in Atlanta. Critics said the accidents highlighted an even greater danger – the efforts at some labs to create superstrains of deadly viruses (what is called “gain of function” research). “You can have all the safety procedures in the world, but you can’t provide for human error,” a critic of gain-of-function research said.

    • view counter

  • NIH employees not notified of smallpox virus vials found at NIH Md. campus

    When Food and Drug Administration(FDA) workers the other day discovered decades-old vials of smallpox virus in Building 29A on the Bethesda, Maryland campus of the National Institutes of Health(NIH), NIH officials reached out to Montgomery County officials, Maryland health officials, and senior NIH executives.No notification, however, was sent to the roughly 18,000 NIH employees who work at the agency’s main campus.

  • Smallpox vials found unguarded at NIH campus in Bethesda, Md.

    Earlier this month workers clearing out a Food and Drug Administration(FDA) branch office at the National Institutes of Health(NIH) campus in Bethesda, Maryland, discovered vials containing smallpox, an eradicated agent feared for its bioweapons potential. The last smallpox samples in existence were thought to be held at tightly guarded facilities in Atlanta and the State Research Center of Virology and Biotechnologyin Novosibirsk, Russia. The vials appear to date from the 1950s.

    • view counter

  • CDC says anthrax infection “highly unlikely,” but reassigns bioterror lab chief

    The U.S. Centers for Disease Control and Prevention(CDC) has advised some of its employees to stop taking antibiotics meant to fight a possible anthrax infection after preliminary tests suggest that it is “highly unlikely” those employees were exposed to live anthrax following an incident in June. Michael Farrell, head of the CDC bioterror lab, has been reassigned.

  • Canada donates Biosafety Level 3 modular laboratory to Caribbean health authorities

    The Biological Security program of Canada’s Global Partnership Program(GPP) has officially transferred a new biological containment laboratory to the Caribbean Public Health Agency(CARPHA). The Biosafety Level 3 (BSL-3) modular laboratory facility, a first in the Caribbean and located in Port of Spain, Trinidad and Tobago, improves diagnostic capabilities for human and veterinary pathogens with high epidemic potential.

  • Leidos awarded DHS Plum Island biolab contract

    DHS awarded Reston, Virginia-based Leidos a prime contract to support and supplement the Science and Technology (S&T) Agricultural Scientific Program at the Plum Island Animal Disease Center (PIADC). The single-award time and materials (T&M) contract has a one-year base period of performance, four one-year options, and a total contract value of approximately $12 million if all options are exercised. Work will be performed in Orient Point, New York.

  • New biodefense centers offer modernized approach, face criticism

    A new facility at Texas A&M University is one of three new biodefense centers created by the U.S. Department of Health and Human Services (HHS) to revolutionize the way fatal viruses are countered in the event of an emergency. The $286-million lab features mobile clean rooms that can be detached and moved to form different production or testing systems as the need arises. Not everyone agrees that the design and capabilities of the new center would offer the best response to biothreats.

  • Amid controversy, Boston City council debates banning Level 4 Biolab

    Boston has long been seen as “America’s Medical Capital,” but that may soon change if the city passes a measure to ban Level 4 Biolab disease research at Boston University’s National Emerging Infectious Diseases Laboratory – research which includes deadly and untreatable strains that could decimate an exposed urban population in the event of an accident or terrorist activity.

  • Concerns grow over repeated safety failures at U.S. BioLabs

    According to a report that was released by the Government Accountability Office (GAO) late last month, the United States is at a high risk for accidents at laboratories which conduct research on potential bioterror germs such as anthrax because federal officials have failed to develop national standards for lab design, construction, and operation.

  • Audits find “troubling” security flaws in CDC labs

    Laboratories at the Centers for Disease Control Prevention (CDC) have been cited in  government audits for  failing to  secure  bioterror agents such as  anthrax and plague. The audits also found that  employees handling these agents have not been trained properly to do so.

  • DHS awards contract for utility plant at the Kansas biolab

    DHS has awarded a $40 million contract to build a utility plant at a $1.15 billion animal research lab in Kansas. The 87,000 square foot facility will replace an animal research lab on Plum Island in New York and will be used to research deadly animal diseases that affect livestock.

  • Government considering options for post-biolab Plum Island

    The Plum Island biolab, located on an 840-acre island of the tip of Long Island, has always been shrouded in mystery owing to the sensitive nature of the biological research done in its high-security facilities; now the center is being shut down by DHS, and the government is considering several options regarding what should be done on the island and the research facility